| 2024-04-09 | +76.7% | news | Seeking Alpha | Acrivon Therapeutics stock surges on $130M private placement financing |
| 2024-04-09 | +76.7% | news | TradingView | ACRV Stock Price and Chart — NASDAQ:ACRV - TradingView |
| 2025-03-26 | -51.8% | news | Investing.com UK | ACRV stock touches 52-week low at $4 amid market challenges - Investing.com UK |
| 2023-03-20 | -42.0% | news | Seeking Alpha | Acrivon Therapeutics stock plunges nearly 30% |
| 2026-01-08 | -41.3% | news | Quiver Quantitative | Acrivon Therapeutics Stock (ACRV) Opinions on Clinical Data Release | ACRV Stock News - Quiver Quantitative |
| 2026-01-08 | -41.3% | news | Investing.com | Acrivon Therapeutics stock plunges after mixed cancer trial results - Investing.com |
| 2026-01-08 | -41.3% | news | TipRanks | Acrivon Therapeutics Stock (ACRV) Sinks despite Positive Cancer Trial Results - TipRanks |
| 2026-01-08 | -41.3% | news | Stock Titan | New cancer drugs show tumor shrinkage in early trials - Stock Titan |
| 2026-01-08 | -41.3% | news | Benzinga | Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga |
| 2026-01-08 | -41.3% | news | StocksToTrade | Acrivon Therapeutics Inc.: Rise or Retreat? - StocksToTrade |
| 2026-01-08 | -41.3% | news | TipRanks | Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks |
| 2026-01-08 | -41.3% | news | TipRanks | Acrivon Showcases Promising Phase 2b Oncology Data Update - TipRanks |
| 2026-01-08 | -41.3% | news | Benzinga | Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2025-04-14 | +32.0% | news | Yahoo Finance | Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - Yahoo Finance |
| 2023-12-01 | +29.3% | news | Seeking Alpha | Acrivon Therapeutics files for $300M mixed shelf |
| 2026-01-06 | +28.6% | news | Stock Titan | New data on experimental cancer drugs ACR-368 and ACR-2316 coming - Stock Titan |
| 2026-01-06 | +28.6% | news | Quiver Quantitative | Acrivon Therapeutics to Release Clinical Data Updates on ACR-368 and ACR-2316 on January 8, 2026 - Quiver Quantitative |
| 2023-04-05 | -24.8% | news | CoinCodex | Acrivon Therapeutics, Inc. Common Stock (ACRV) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2023-11-09 | -23.7% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.66 beats by $0.04 |
| 2025-04-25 | -22.9% | news | Stock Titan | ACRV Stock Price, News & Analysis - Stock Titan |
| 2025-04-25 | -22.9% | news | StocksToTrade | Acrivon Therapeutics Inc. Shares Surge: Time to Invest? - StocksToTrade |
| 2025-03-28 | -18.1% | earnings | Seeking Alpha | Acrivon Therapeutics reports Q4 results |
| 2025-03-28 | -18.1% | news | Yahoo Finance | Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance |
| 2025-03-28 | -18.1% | news | Intellectia AI | ACRV Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2026-02-27 | -16.4% | news | MarketBeat | Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer |
| 2026-02-27 | -16.4% | news | Investing.com | Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com |
| 2024-03-28 | +12.3% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.86 |
| 2024-04-17 | +12.1% | news | Seeking Alpha | Acrivon Therapeutics files to sell 15.29M shares of common stock for holders |
| 2025-03-27 | -11.9% | news | Moomoo | Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Moomoo |
| 2026-03-02 | +11.4% | analyst | Investing.com | Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com |
| 2025-08-13 | +10.8% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.55 |
| 2026-03-03 | +10.6% | analyst | Zacks | Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why |
| 2026-03-03 | +10.6% | analyst | Yahoo Finance | Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance |
| 2026-03-03 | +10.6% | executive | Stock Titan | Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan |
| 2026-02-24 | +10.4% | news | GlobeNewswire | Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference |
| 2026-04-17 | +10.4% | analyst | GlobeNewswire | Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities |
| 2026-04-17 | +10.4% | news | Stock Titan | Cancer drug pairing drove complete tumor regression in Acrivon lab study - Stock Titan |
| 2024-08-13 | -9.5% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.52 |
| 2025-02-05 | +9.4% | legal | Seeking Alpha | Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer |
| 2025-02-12 | +8.4% | news | Yahoo Finance | We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Yahoo Finance |
| 2023-03-28 | -8.1% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.80 beats by $0.58 |
| 2024-04-02 | -7.6% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-03-27 | -7.1% | news | simplywall.st | We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate - simplywall.st |
| 2026-01-16 | +6.9% | executive | Investing.com | Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com |
| 2024-01-03 | -6.0% | executive | Seeking Alpha | Acrivon Therapeutics appoints Jean-Marie Cuillerot as Chief Medical Officer |
| 2026-04-21 | +5.6% | executive | Stock Titan | Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes - Stock Titan |
| 2026-03-23 | -5.5% | news | Stock Titan | [SCHEDULE 13D/A] Acrivon Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan |
| 2025-10-02 | +5.4% | news | simplywall.st | Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st |
| 2026-03-24 | -5.2% | analyst | Investing.com | Citizens reiterates Acrivon Therapeutics stock rating on endometrial cancer trial progress - Investing.com |
| 2024-05-28 | -5.0% | news | Zacks Investment Research | Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock - Zacks Investment Research |
| 2024-11-13 | -5.0% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.59 |
| 2023-03-26 | +4.7% | news | Seeking Alpha | Acrivon: Precision-Testing Your Trial Patients Before Enrolment |
| 2023-03-25 | +4.7% | earnings | TradingView | Acrivon Therapeutics, Inc. Earnings and Revenue – NASDAQ:ACRV - TradingView |
| 2024-12-12 | -4.6% | news | Seeking Alpha | Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis |
| 2022-11-16 | -4.5% | earnings | MarketBeat | Acrivon Therapeutics (ACRV) Stock Price, News & Analysis - MarketBeat |
| 2022-11-16 | -4.5% | earnings | MarketBeat | Acrivon Therapeutics (ACRV) Earnings Date and Reports 2026 - MarketBeat |
| 2023-05-13 | +4.4% | earnings | Seeking Alpha | Stocks To Watch: Retail Earnings, Debt Standoff And ChatGPT Goes To DC |
| 2026-03-04 | -4.3% | news | Seeking Alpha | Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow |
| 2026-03-04 | -4.3% | news | Seeking Alpha | Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026 - Slideshow |
| 2025-05-05 | -4.3% | news | Yahoo Finance | Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance |
| 2024-06-13 | -4.2% | news | Seeking Alpha | Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias? |
| 2026-04-06 | -3.8% | news | Xã Thanh Hà | Can Acrivon (ACRV) Stock Go Higher | Price at $1.61, Up 5.92% - IPO Watch - Xã Thanh Hà |
| 2025-09-18 | +3.8% | news | Investing.com | Acrivon Therapeutics’ SWOT analysis: precision oncology stock at crossroads - Investing.com |
| 2026-04-23 | -3.4% | news | Stock Titan | RA Capital funds add 3,888,888 Acrivon (ACRV) shares at $1.80 - Stock Titan |
| 2026-04-23 | -3.4% | news | Stock Titan | RA Capital boosts Acrivon (ACRV) stake to 28.8% after ATM share buy - Stock Titan |
| 2024-05-11 | -3.3% | earnings | MarketBeat | Acrivon Therapeutics (ACRV) Stock Forecast and Price Target 2026 - MarketBeat |
| 2026-03-19 | +3.2% | news | GlobeNewswire | Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights |
| 2026-03-19 | +3.2% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.49 misses by $0.01 |
| 2026-03-19 | +3.2% | news | Stock Titan | Cancer drug study posts 52% response as Acrivon adds new arm - Stock Titan |
| 2026-03-19 | +3.2% | analyst | Investing.com | Oppenheimer reiterates Acrivon stock rating on endometrial cancer focus - Investing.com |
| 2026-03-19 | +3.2% | news | Stock Titan | Acrivon Therapeutics (ACRV) posts 2025 results, 52% ACR-368 response and $118.6M cash - Stock Titan |
| 2026-03-19 | +3.2% | news | GlobeNewswire | Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire |
| 2023-08-11 | +3.0% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.63 beats by $0.01 |
| 2025-07-22 | +2.7% | news | Yahoo Finance | Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance |
| 2025-11-28 | +2.5% | analyst | Yahoo Finance | H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Yahoo Finance |
| 2026-03-17 | -2.4% | news | GlobeNewswire | Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors |
| 2026-03-17 | -2.4% | news | GlobeNewswire | Acrivon Therapeutics to Present Pre-Clinical AP3 Data at - GlobeNewswire |
| 2023-06-02 | -2.4% | analyst | TradingView | ACRV Forecast — Price Target — Prediction for 2027 - TradingView |
| 2023-05-09 | +2.3% | legal | Seeking Alpha | Acrivon's ACR-368 for ovarian, uterus cancers gets FDA fast track designations |
| 2026-02-23 | -1.7% | news | GlobeNewswire | Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress |
| 2024-09-18 | -1.5% | earnings | Seeking Alpha | Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects |
| 2024-09-18 | -1.5% | earnings | Seeking Alpha | Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha |
| 2022-12-12 | -1.5% | news | ChartMill | ACRV Stock Price, Quote & Chart | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill |
| 2025-05-01 | -1.5% | news | Investing.com | Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com |
| 2026-02-18 | -1.5% | expansion | GlobeNewswire | Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory |
| 2025-03-24 | -1.5% | news | Investing.com | Citizens JMP reiterates Acrivon stock with $17 target - Investing.com |
| 2026-01-19 | +1.0% | news | simplywall.st | Penny Stocks To Watch In January 2026 - simplywall.st |
| 2026-01-18 | +1.0% | news | Yahoo Finance | Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance |
| 2026-01-18 | +1.0% | news | simplywall.st | Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st |
| 2026-04-15 | +0.8% | news | GlobeNewswire | Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-15 | +0.8% | earnings | MarketBeat | Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat |
| 2026-04-15 | +0.8% | news | Stock Titan | New Acrivon employee gets stock options for 111,150 shares - Stock Titan |
| 2023-03-10 | +0.3% | news | ChartMill | ACRV Technical Analysis | Trend, Signals & Chart Patterns | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill |
| 2024-05-14 | +0.3% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.73 beats by $0.11 |
| 2025-05-15 | -0.2% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 |
| 2025-05-15 | -0.2% | news | Intellectia AI | ACRV Forecast — Price Prediction for 2026. Should I Buy ACRV? - Intellectia AI |
| 2022-12-15 | -0.1% | earnings | Zacks Investment Research | What date does Acrivon Therapeutics, Inc.'s (ACRV) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2025-11-13 | -0.1% | earnings | Seeking Alpha | Acrivon Therapeutics GAAP EPS of -$0.47 beats by $0.12 |
| 2026-04-24 | — | news | StocksToTrade | Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade |
| 2022-11-15 | — | news | Seeking Alpha | Acrivon stock jumps 33% following $94M IPO, shares price below range (update) |
| 2022-11-15 | — | news | Stock Titan | Latest ACRV News - Acrivon to Highlight Preclinical Data with ... - Stock Titan |